Biogen Inc.

Biogen Inc. BDR
Stock Exchange Brazilian Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
1.21 B
Public Float
-
Biogen Inc.
Stock Exchange NASDAQ Stock Market
EPS
$23.21
Market Cap
$45.42 B
Shares Outstanding
193.89 M
Public Float
196.38 M
Biogen Inc.
Stock Exchange Santiago Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
211.01 M
Public Float
210.43 M
Biogen Inc.
Stock Exchange SIX Swiss Exchange
EPS
-
Market Cap
-
Shares Outstanding
201.44 M
Public Float
210.43 M

Profile

Address
225 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.biogen.com
Updated 07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Financials

View All
Created with Highcharts 5.0.14Biogen Inc.Net Income. Fiscal year is January-December. All values USD Millions.1 8621 8622 9352 9353 5473 5473 7033 7032 5392 5394 4314 43120132014201520162017201801k2k3k4k5k
Created with Highcharts 5.0.14Biogen Inc.Sales/Revenue. Fiscal year is January-December. All values USD Millions.5 8605 8608 5828 5829 3219 32110 19410 19410 99010 99012 05312 05320132014201520162017201802.5k5k7.5k10k12.5k15k

Michel Vounatsos
Chief Executive Officer & Director
Stelios B. Papadopoulos
Chairman